PR94684

LONDON, March 1, 2022 /PRNewswire=KYODO JBN/ --

-- Boehringer Ingelheim partners with Lifebit Biotech, Ltd. to build a scalable

data, analytics, and infrastructure platform

-- This collaboration aims at capturing translational disease insights from

large external healthcare biobanks and maximizing value of data for drug

discovery and precision medicine

The leading research-driven biopharmaceutical company Boehringer Ingelheim and

precision medicine software company Lifebit Biotech, Ltd. (Lifebit) today

announce partnership in which Lifebit will support Boehringer Ingelheim in

building a scalable data, analytics, and infrastructure platform within its IT

environment.

Logo - https://mma.prnewswire.com/media/1752753/Boehringer_Ingelheim_Logo.jpg

Logo - https://mma.prnewswire.com/media/1752754/lifebit_logo.jpg

"This platform will play an important part of Boehringer Ingelheim's broader

strategy to capture translational disease insights from large external

healthcare biobanks and ultimately to accelerate the development of innovative

medicines," commented Dr. Jan Nygaard Jensen, SVP and global Head of

Computational Biology and Digital Sciences at Boehringer Ingelheim. Lifebit's

transformational solutions and services will provide standardization of data

sources and types, data curation, identification of data and services that

could be migrated to cloud, and federating data connectivity with third parties.

A key element of this partnership involves Lifebit's CloudOS platform - a

powerful, secure and cutting-edge platform used by a growing number of research

organizations and governments globally, such as Genomics England and The Hong

Kong Genome Project. The federated architecture of this platform securely

brings analytics and computing tools to the data rather than moving sensitive

data around. This promises to unlock the transformational value of biomedical

data by enabling seamless integration with world-leading population genomics

and disease-focused cohorts. Another key benefit of Lifebit's CloudOS will be

the provision of powerful analytic capabilities and global biobank connections

to build a secure "dataland" for analytics and research.

This collaboration follows on the partnership announced in 2021 on utilizing

the Lifebit REAL platform to accelerate detection of the latest disease

outbreaks including transboundary diseases and emerging pathogens, such as

COVID-19.

Lifebit CEO Dr. Maria Chatzou Dunford shared: "We are thrilled to contribute to

Boehringer Ingelheim's vision of harnessing the power of external biobanks and

large-scale clinico-genomic data to transform R&D. We are excited to see how

our technology and global biobank partnerships can transform research

capabilities for Boehringer Ingelheim and deliver powerful impacts for clinical

development pipelines across disease areas."

"We are continuously on the lookout for new opportunities to be able to deliver

faster, better and safer solutions. Therefore, partnering with Lifebit, one of

our partners in this area, is so critical as data and digital technologies can

feed into meaningful scientific exploration, accelerate patient benefits, and

ultimately lead to improved health," added Markus Schümmelfeder, Head of IT at

Boehringer Ingelheim.

About Lifebit Biotech, Ltd.

Lifebit builds enterprise data platforms for use by organisations with complex

and sensitive biomedical datasets. Lifebit's patented federated technology

securely unlocks access to biomedical data. From providing Trusted Research

Environments for national precision medicine programmes to enabling

pharmaceutical companies to discover new drug targets faster, Lifebit empowers

customers to transform how they leverage sensitive biomedical data.

About Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that improve the

lives of humans and animals. As a leading research-driven biopharmaceutical

company, the company creates value through innovation in areas of high unmet

medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim

takes a long-term perspective. Around 52,000 employees serve more than 130

markets in the three business areas, Human Pharma, Animal Health, and

Biopharmaceutical Contract Manufacturing.

More information about Boehringer Ingelheim can be found at

www.boehringer-ingelheim.com

Boehringer Ingelheim's Intended Audiences Notice

This press release is issued from our Corporate Headquarters in Ingelheim,

Germany and is intended to provide information about our global business.

Please be aware that information relating to the approval status and labels of

approved products may vary from country to country, and a country-specific

press release on this topic may have been issued in the countries where we do

business.

SOURCE: Lifebit Biotech, Ltd.

CONTACT: Bettina Dold, +1-412-983-0048, bettina@lifebit.ai